[
  {
    "disease": "cancer",
    "research_areas": [
      "rationale_executive_summary",
      "disease_overview",
      "therapeutic_landscape",
      "current_treatment_guidelines",
      "competitor_analysis",
      "clinical_trials_analysis",
      "market_opportunity_analysis"
    ],
    "sections": [
      {
        "name": "rationale_executive_summary",
        "description": "This section will provide a concise summary of the key findings and recommendations for the use of low-dose IL-2 in cancer. It will outline the therapeutic mechanism, the specific unmet needs in oncology that it could address, a brief overview of supporting pre-clinical and clinical evidence, and any relevant regulatory history or designations for IL-2 in cancer.",
        "required_evidence_types": [
          "google",
          "pubmed",
          "press_release"
        ],
        "key_questions": [
          "What is the core rationale and therapeutic mechanism for using low-dose IL-2 as an immunotherapy support in cancer?",
          "What are the primary unmet needs in current cancer treatment paradigms that low-dose IL-2 aims to fill?",
          "What is the high-level summary of the most significant pre-clinical and clinical evidence supporting low-dose IL-2 for cancer?",
          "Are there any existing FDA/EMA designations (e.g., Orphan Drug, Fast Track) for IL-2 therapies in the context of cancer?"
        ],
        "scope": "The scope is a high-level executive summary focused exclusively on low-dose IL-2 for cancer. It should synthesize information from all other sections of the report into a brief, compelling overview. It must exclude in-depth data, detailed trial results, and information on other diseases."
      },
      {
        "name": "disease_overview",
        "description": "This section will deliver a detailed overview of cancer, covering its general characteristics, epidemiology in the US market, diagnostic procedures, and pathophysiology relevant to IL-2's mechanism of action. It will also identify key biomarkers used in oncology and discuss potential patient populations with cancer for whom low-dose IL-2 may be contraindicated.",
        "required_evidence_types": [
          "pubmed",
          "google",
          "guideline"
        ],
        "key_questions": [
          "What are the defining characteristics, common symptoms, and mortality/morbidity associated with cancer as a whole?",
          "What is the current incidence and prevalence of cancer in the United States?",
          "How is cancer typically diagnosed, and are there significant diagnostic delays that could impact treatment?",
          "What is the pathophysiology of cancer, specifically the aspects of the tumor microenvironment and immune response that are targeted by low-dose IL-2?",
          "What are the most common, clinically validated biomarkers used for diagnosis and prognosis in cancer care?",
          "Which patient subpopulations with cancer might be excluded from low-dose IL-2 therapy due to contraindications?"
        ],
        "scope": "This section must focus solely on the disease overview of cancer. Given the breadth of the topic, the focus should be on general oncologic principles relevant to immunotherapy. It should not discuss specific treatments in detail, as that is covered in other sections. It must specify whether IL-2 aims to treat the underlying disease or alleviate symptoms."
      },
      {
        "name": "therapeutic_landscape",
        "description": "This section will map out the current therapeutic landscape for cancer. It will systematically list approved therapies, competing immunomodulators in development, and other key pipeline assets, structured in tables as specified in the report guidance.",
        "required_evidence_types": [
          "google",
          "press_release",
          "guideline",
          "other"
        ],
        "key_questions": [
          "What are the currently FDA-approved therapies for cancer, particularly those with immunomodulatory mechanisms?",
          "Which competing immunomodulators are currently in development for cancer, and what is their status (preclinical, clinical phase)?",
          "What other significant non-immunomodulatory therapies are in the development pipeline for cancer?",
          "For each therapy, who is the owner, what is its mechanism of action, and what is its reported efficacy in cancer?"
        ],
        "scope": "The scope is limited to therapies for cancer. The section should be structured to present information clearly in the table formats requested in the prompt. It provides a broad overview of all treatments, which will be narrowed down to direct competitors in the 'Competitor Analysis' section."
      },
      {
        "name": "current_treatment_guidelines",
        "description": "This section will summarize the current, major treatment guidelines for cancer from authoritative bodies (e.g., NCCN, ASCO) and propose how low-dose IL-2 could be integrated into these established treatment algorithms.",
        "required_evidence_types": [
          "guideline",
          "pubmed"
        ],
        "key_questions": [
          "What do the current major clinical practice guidelines recommend for the treatment of cancer, particularly concerning the use of immunotherapies?",
          "Where in the existing treatment pathways for cancer could low-dose IL-2 be positioned (e.g., first-line, adjuvant, in combination)?",
          "What evidence would be required to support the inclusion of low-dose IL-2 in future cancer treatment guidelines?"
        ],
        "scope": "Focus exclusively on established, evidence-based treatment guidelines for cancer from major professional organizations. The analysis should be on the potential strategic positioning of low-dose IL-2 within these guidelines, not just a restatement of the guidelines themselves."
      },
      {
        "name": "competitor_analysis",
        "description": "This section will conduct a focused analysis of direct competitors to low-dose IL-2 therapy specifically for cancer. It will summarize information on these competitors, their potential market impact, and relevant market trends in the oncology space.",
        "required_evidence_types": [
          "google",
          "press_release",
          "pubmed"
        ],
        "key_questions": [
          "Which companies are developing direct competitors to low-dose IL-2 for cancer (e.g., other IL-2 variants, IL-2 mimetics, IL-15 agonists)?",
          "What is the mechanism of action, development status, and publicly available data for these competing assets?",
          "What is the potential market impact of these direct competitors on a future low-dose IL-2 product for cancer?",
          "What are the key market trends in immuno-oncology that could affect the competitive positioning of low-dose IL-2?"
        ],
        "scope": "The analysis must be tightly focused on *direct* competitors, defined as therapies with a similar mechanism of action (e.g., Treg modulation via the IL-2 pathway) for cancer. It should exclude the broader therapeutic landscape covered in the earlier section."
      },
      {
        "name": "clinical_trials_analysis",
        "description": "This section will provide a comprehensive analysis of clinical trials that have studied low-dose IL-2 specifically for cancer. The trials will be categorized as completed, recruiting/active, or terminated/unknown, and presented in the specified table format.",
        "required_evidence_types": [
          "clinicaltrials",
          "pubmed"
        ],
        "key_questions": [
          "What completed clinical trials have evaluated low-dose IL-2 in cancer, and what were their designs, endpoints, enrollment, and key efficacy and toxicity results?",
          "What clinical trials of low-dose IL-2 in cancer are currently active, recruiting, or not yet recruiting, and what are their key design parameters?",
          "Have any clinical trials of low-dose IL-2 in cancer been terminated or withdrawn, and what were the reasons?",
          "For each completed trial, is there a corresponding publication with detailed results?"
        ],
        "scope": "This analysis is strictly limited to clinical trials of low-dose IL-2 used for cancer. High-dose IL-2 trials should be excluded. The output must adhere to the detailed table formats outlined in the project guidance, including NCTID, sponsor, design, endpoints, and results."
      },
      {
        "name": "market_opportunity_analysis",
        "description": "This section will assess the commercial opportunity for a low-dose IL-2 therapy in the cancer market. It will cover the potential market size, relevant patents, special regulatory designations, the competitor landscape's impact, unmet needs, and how the asset could be differentiated from existing treatments.",
        "required_evidence_types": [
          "google",
          "press_release",
          "pubmed",
          "other"
        ],
        "key_questions": [
          "What is the estimated potential market size for immuno-oncology therapies in the US for cancer?",
          "Are there any key patents related to low-dose IL-2 formulations or its use in cancer that could impact market entry?",
          "Has low-dose IL-2 or any similar formulation received special regulatory designations from the FDA for cancer?",
          "What specific unmet needs exist in the current cancer treatment landscape that low-dose IL-2 can address?",
          "How can low-dose IL-2 be differentiated from current and pipeline therapies in terms of efficacy, toxicity, cost, or administration?",
          "What is the annual incidence (number of new cases) of cancer in the US?"
        ],
        "scope": "The scope is a commercial and strategic analysis of the market opportunity for low-dose IL-2 in cancer. The analysis should be forward-looking and based on evidence gathered throughout the report. It must remain focused on the US market as specified."
      }
    ]
  },
  {
    "continue_research": true,
    "gaps": [
      {
        "section": "therapeutic_landscape",
        "missing_evidence_types": [
          "clinicaltrials"
        ],
        "missing_questions": [
          "What emerging therapies are in development for CRSwNP?"
        ],
        "notes": "The evidence store is still missing clinical trial data, which is crucial for identifying emerging therapies and validating the current landscape."
      },
      {
        "section": "competitor_analysis",
        "missing_evidence_types": [
          "clinicaltrials",
          "press_release"
        ],
        "missing_questions": [
          "What are the mechanisms of action of competitor drugs?",
          "What is the development stage and recent news for competing therapies?"
        ],
        "notes": "This section has an insufficient number of evidence items (only 2) and is missing required evidence types. Key questions about competitor pipelines remain unanswered."
      }
    ],
    "tasks": [
      {
        "section": "therapeutic_landscape",
        "evidence_type": "clinicaltrials",
        "query": "emerging therapies Chronic Rhinosinusitis with Nasal Polyps",
        "preferred_tool": "clinicaltrials_search_studies",
        "priority": "high"
      },
      {
        "section": "competitor_analysis",
        "evidence_type": "clinicaltrials",
        "query": "omalizumab OR mepolizumab OR benralizumab for Chronic Rhinosinusitis with Nasal Polyps",
        "preferred_tool": "clinicaltrials_search_studies",
        "priority": "high"
      },
      {
        "section": "competitor_analysis",
        "evidence_type": "press_release",
        "query": "Xolair (omalizumab) OR Nucala (mepolizumab) Chronic Rhinosinusitis with Nasal Polyps press release",
        "preferred_tool": "google_search",
        "priority": "medium"
      }
    ]
  },
  {
    "continue_research": true,
    "gaps": [
      {
        "section": "therapeutic_landscape",
        "missing_evidence_types": [
          "clinicaltrials"
        ],
        "missing_questions": [
          "What emerging therapies are in development for CRSwNP?"
        ],
        "notes": "The evidence store is still missing clinical trial data, which is crucial for identifying emerging therapies and validating the current landscape."
      },
      {
        "section": "competitor_analysis",
        "missing_evidence_types": [
          "clinicaltrials",
          "press_release"
        ],
        "missing_questions": [
          "What are the mechanisms of action of competitor drugs?",
          "What is the development stage and recent news for competing therapies?"
        ],
        "notes": "This section has an insufficient number of evidence items (only 2) and is missing required evidence types. Key questions about competitor pipelines remain unanswered."
      }
    ],
    "tasks": [
      {
        "section": "therapeutic_landscape",
        "evidence_type": "clinicaltrials",
        "query": "emerging therapies Chronic Rhinosinusitis with Nasal Polyps",
        "preferred_tool": "clinicaltrials_search_studies",
        "priority": "high"
      },
      {
        "section": "competitor_analysis",
        "evidence_type": "clinicaltrials",
        "query": "omalizumab OR mepolizumab OR benralizumab for Chronic Rhinosinusitis with Nasal Polyps",
        "preferred_tool": "clinicaltrials_search_studies",
        "priority": "high"
      },
      {
        "section": "competitor_analysis",
        "evidence_type": "press_release",
        "query": "Xolair (omalizumab) OR Nucala (mepolizumab) Chronic Rhinosinusitis with Nasal Polyps press release",
        "preferred_tool": "google_search",
        "priority": "medium"
      }
    ]
  },
  {
    "continue_research": true,
    "gaps": [
      {
        "section": "therapeutic_landscape",
        "missing_evidence_types": [
          "clinicaltrials"
        ],
        "missing_questions": [
          "What emerging therapies are in development for CRSwNP?"
        ],
        "notes": "The evidence store is still missing clinical trial data, which is crucial for identifying emerging therapies and validating the current landscape."
      },
      {
        "section": "competitor_analysis",
        "missing_evidence_types": [
          "clinicaltrials",
          "press_release"
        ],
        "missing_questions": [
          "What are the mechanisms of action of competitor drugs?",
          "What is the development stage and recent news for competing therapies?"
        ],
        "notes": "This section has an insufficient number of evidence items (only 2) and is missing required evidence types. Key questions about competitor pipelines remain unanswered."
      }
    ],
    "tasks": [
      {
        "section": "therapeutic_landscape",
        "evidence_type": "clinicaltrials",
        "query": "emerging therapies Chronic Rhinosinusitis with Nasal Polyps",
        "preferred_tool": "clinicaltrials_search_studies",
        "priority": "high"
      },
      {
        "section": "competitor_analysis",
        "evidence_type": "clinicaltrials",
        "query": "omalizumab OR mepolizumab OR benralizumab for Chronic Rhinosinusitis with Nasal Polyps",
        "preferred_tool": "clinicaltrials_search_studies",
        "priority": "high"
      },
      {
        "section": "competitor_analysis",
        "evidence_type": "press_release",
        "query": "Xolair (omalizumab) OR Nucala (mepolizumab) Chronic Rhinosinusitis with Nasal Polyps press release",
        "preferred_tool": "google_search",
        "priority": "medium"
      }
    ]
  },
  {
    "continue_research": false,
    "gaps": [],
    "tasks": []
  },
  {
    "metadata": {
      "generated_at": "2024-05-22T10:30:00Z",
      "model": "writer_agent"
    },
    "indication_profile": {
      "disease_name": "Hepatocellular Carcinoma",
      "ontology_ids": [
        "MONDO:0005273",
        "DOID:684"
      ],
      "icd_10_codes": [
        "C22.0"
      ],
      "patient_population_us": 41000,
      "key_biomarkers": [
        {
          "name": "Alpha-fetoprotein (AFP)",
          "role": "prognostic",
          "ontology_ids": [
            "HGNC:320"
          ]
        }
      ]
    },
    "mechanistic_rationales": [
      {
        "mechanism_name": "PD-L1/PD-1 Blockade",
        "relevance_score": "high",
        "evidence_ids": [
          "mechanism_of_action_E1",
          "mechanism_of_action_E3"
        ],
        "status": "established",
        "confidence": 0.95
      },
      {
        "mechanism_name": "VEGF Inhibition (in combination with bevacizumab)",
        "relevance_score": "high",
        "evidence_ids": [
          "mechanism_of_action_E1",
          "mechanism_of_action_E2"
        ],
        "status": "established",
        "confidence": 0.95
      }
    ],
    "competitive_landscape": [
      {
        "company_name": "Eisai Inc./Merck",
        "drug_name": "Lenvatinib (Lenvima)",
        "mechanism": "Multi-kinase inhibitor (including VEGFR1-3)",
        "stage": "approved",
        "nct_ids": [],
        "evidence_ids": [
          "competitive_landscape_E1"
        ]
      },
      {
        "company_name": "Bayer",
        "drug_name": "Sorafenib (Nexavar)",
        "mechanism": "Multi-kinase inhibitor (including VEGFR, PDGFR)",
        "stage": "approved",
        "nct_ids": [],
        "evidence_ids": [
          "competitive_landscape_E2"
        ]
      },
      {
        "company_name": "AstraZeneca",
        "drug_name": "Durvalumab + Tremelimumab (IMFINZI + IMJUDO)",
        "mechanism": "PD-L1 inhibitor + CTLA-4 inhibitor",
        "stage": "approved",
        "nct_ids": [
          "NCT03298451"
        ],
        "evidence_ids": [
          "competitive_landscape_E3"
        ]
      }
    ],
    "drug_specific_trials": [
      {
        "nct_id": "NCT03434379",
        "trial_status": "completed",
        "phase": "phase_3",
        "intervention_name": "Atezolizumab",
        "dose": "1200 mg",
        "route": "iv",
        "design": "Randomized, open-label, multicenter study comparing atezolizumab plus bevacizumab versus sorafenib.",
        "enrollment": 501,
        "sponsor": "Hoffmann-La Roche",
        "primary_outcome_met": "yes",
        "evidence_ids": [
          "clinical_trials_E1"
        ]
      },
      {
        "nct_id": "NCT04713594",
        "trial_status": "recruiting",
        "phase": "phase_2",
        "intervention_name": "Atezolizumab",
        "dose": "1200 mg",
        "route": "iv",
        "design": "Single arm study of atezolizumab and bevacizumab in combination with Y-90 radioembolization for HCC.",
        "enrollment": 28,
        "sponsor": "National Cancer Institute (NCI)",
        "primary_outcome_met": "pending",
        "evidence_ids": [
          "clinical_trials_E2"
        ]
      }
    ],
    "provenance": [
      {
        "key": "disease_overview",
        "value": [
          "disease_overview_E1",
          "disease_overview_E2",
          "disease_overview_E3"
        ]
      },
      {
        "key": "standard_of_care",
        "value": [
          "standard_of_care_E1",
          "standard_of_care_E2"
        ]
      },
      {
        "key": "mechanism_of_action",
        "value": [
          "mechanism_of_action_E1",
          "mechanism_of_action_E2",
          "mechanism_of_action_E3"
        ]
      },
      {
        "key": "clinical_trials",
        "value": [
          "clinical_trials_E1",
          "clinical_trials_E2"
        ]
      },
      {
        "key": "competitive_landscape",
        "value": [
          "competitive_landscape_E1",
          "competitive_landscape_E2",
          "competitive_landscape_E3"
        ]
      }
    ]
  }
]